Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…
Read More
Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom
Eli Lilly has formally agreed to acquire AtaiBeckley for a substantial sum, comprising $2.8 billion upfront and an additional $1…
Read More
Breakthrough Molecule OLE Offers New Hope for Restoring Brain Immune Function in Alzheimer Disease Patients
In a significant advancement for neurodegenerative research, a collaborative team of scientists from Spain and Switzerland has identified an experimental…
Read More
Experimental Molecule OLE Identified as Potential Breakthrough in Restoring Microglial Function and Combating Alzheimers Disease
Researchers at the Institute for Neurosciences in Spain and the École Polytechnique Fédérale de Lausanne in Switzerland have announced the…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant reordering in fiscal year 2025, as revealed by the latest "Pharma 50"…
Read More
Uncovering the Stop Scratching Signal Scientists Identify TRPV4 Molecule as Key to Regulating Itch Relief
The sensation of an itch, scientifically known as pruritus, is a near-universal human experience, yet the biological mechanisms that govern…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025.
The pharmaceutical industry witnessed a significant shift in its commercial landscape during Fiscal Year 2025, with Merck’s oncology powerhouse, Keytruda…
Read More
King’s College London Scientists Unveil Novel Aluminum Molecule as Sustainable Alternative to Precious Metal Catalysts
A research team at King’s College London has announced the discovery of a pioneering molecular form of aluminum that could…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s immunotherapy blockbuster, Keytruda (pembrolizumab), maintained its dominant position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording…
Read More
Pharma 50: Keytruda Holds Top Brand Slot, But Tirzepatide and Semaglutide Have Already Passed It at the Molecule Level in FY2025
Merck’s Keytruda (pembrolizumab) maintained its formidable position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording an impressive…
Read MoreYOU MAY HAVE MISSED
